Open Collections

UBC Faculty Research and Publications

Group B Streptococcus and Respiratory Syncytial Virus immunization during pregnancy : a landscape analysis Heath, Paul T.; Culley, Fiona J.; Jones, Christine E.; Kampmann, Beate; Le Doare, Kirsty; Nunes, Marta C.; Sadarangani, Manish; Chaudhry, Zain; Baker, Carol J.; Openshaw, Peter J.M.

Abstract

Streptococcus agalactiae or group B Streptococcus (GBS) and Respiratory Syncytial Virus (RSV) are leading causes of infant morbidity and mortality worldwide. There are currently no licensed vaccines for either disease, but vaccines for both are under development. Severe RSV disease can be prevented by passively administered antibody. The presence of maternal RSV-specific IgG antibody is associated with reduced prevalence and severity of RSV disease in the first few weeks of life, while maternal serotype-specific anti-capsular antibody is associated with protection against both early onset (EO) and late onset (LO) GBS disease. Vaccination in pregnancy offers an attractive method of protecting infants against both diseases. This structured review identifies what is known about immune protection against both diseases and identifies knowledge gaps in the immunobiology, with the aim of prioritizing research directions in maternal immunization.

Item Metadata

Title
Group B Streptococcus and Respiratory Syncytial Virus immunization during pregnancy : a landscape analysis
Alternate Title
Group B streptococcus and respiratory syncytial virus immunisation during pregnancy : a landscape analysis
Creator
Heath, Paul T.; Culley, Fiona J.; Jones, Christine E.; Kampmann, Beate; Le Doare, Kirsty; Nunes, Marta C.; Sadarangani, Manish; Chaudhry, Zain; Baker, Carol J.; Openshaw, Peter J.M.
Contributor
Children's Hospital (Vancouver, B.C.). Vaccine Evaluation Center
Date Issued
2017-07
Description
Streptococcus agalactiae or group B Streptococcus (GBS) and Respiratory Syncytial Virus (RSV) are leading causes of infant morbidity and mortality worldwide. There are currently no licensed vaccines for either disease, but vaccines for both are under development. Severe RSV disease can be prevented by passively administered antibody. The presence of maternal RSV-specific IgG antibody is associated with reduced prevalence and severity of RSV disease in the first few weeks of life, while maternal serotype-specific anti-capsular antibody is associated with protection against both early onset (EO) and late onset (LO) GBS disease. Vaccination in pregnancy offers an attractive method of protecting infants against both diseases. This structured review identifies what is known about immune protection against both diseases and identifies knowledge gaps in the immunobiology, with the aim of prioritizing research directions in maternal immunization.
Genre
Article; Postprint
Type
Text
Language
eng
Date Available
2018-04-11
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0365535
URI
http://hdl.handle.net/2429/65283
Affiliation
Medicine, Faculty of; Other UBC; Non UBC; Pediatrics, Department of
Citation
Heath, P. T., Culley, F. J., Jones, C. E., Kampmann, B., Le Doare, K., Nunes, M. C.,...Openshaw, Peter J. M. (2017). Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: A landscape analysis. The Lancet Infectious Diseases, 17(7), E223-E234.
Publisher DOI
10.1016/S1473-3099(17)30232-3
Peer Review Status
Reviewed
Scholarly Level
Faculty; Graduate
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International